An anticoagulant and anti-infection coating for dialysis catheters and its preparation method

By constructing a multi-layer coating on the surface of the dialysis catheter and combining chemical and physical cross-linking technologies, the problem of the single function of existing coatings is solved, and the integration of anticoagulation and anti-infection is achieved. This provides the function of releasing antimicrobial drugs on demand and enhances the stability and antimicrobial effect of the coating.

CN122075805APending Publication Date: 2026-05-26保定市第一中心医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610034122.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-12
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing dialysis catheter coatings have limited functionality, making it difficult to simultaneously achieve anticoagulation and anti-infection effects. Furthermore, the passive release mode cannot respond to changes in the infection microenvironment, leading to drug resistance and cytotoxicity risks.

Method used

A composite layer of covalently grafted poly(2-methacryloyloxyethylphosphorylcholine) and heparin sodium is constructed on the surface of the dialysis catheter, combined with a pH-responsive interpenetrating network hydrogel outer layer loaded with silver nanoparticles and antimicrobial peptides. Through chemical and physical cross-linking, a multilayer coating is formed to achieve the integration of antifouling, anticoagulation and antibacterial properties.

Benefits of technology

It achieves continuous and sustained-release basic antibacterial protection under normal physiological conditions, releases antibacterial drugs on demand during infection, reduces the risk of drug resistance, enhances the adhesion between the coating and the substrate, and improves anticoagulation and antibacterial effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to the field of medical materials technology, and discloses an anticoagulant and anti-infection coating for dialysis catheters and its preparation method. The preparation method includes: pretreatment of the dialysis catheter substrate, preparation of a bridging layer, preparation of an anticoagulant and antifouling functional layer, preparation of an antibacterial gel outer layer, and post-sterilization treatment of the catheter. This invention achieves integrated antifouling, anticoagulant, and antibacterial properties by constructing a covalently grafted composite layer of poly(2-methacryloyloxyethylphosphorylcholine) and heparin sodium on the surface of the dialysis catheter, and then constructing a pH-responsive interpenetrating hydrogel outer layer loaded with silver nanoparticles and antimicrobial peptides on its exterior. Simultaneously, the antibacterial gel outer layer of this invention forms a chemical network with aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt through Schiff base bonds, and interpenetrates with the physical temperature-sensitive mesh of poloxamer F127, jointly encapsulating antibacterial components and achieving pH-responsive release of the antibacterial components.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medical materials technology, and more specifically, to an anticoagulant and anti-infection coating for dialysis catheters and its preparation method. Background Technology

[0002] Long-term indwelling central venous dialysis catheters are a vital lifeline for patients with end-stage renal disease. However, the pathway established by the catheter between the blood and the external environment exposes it to two serious and interconnected complications: catheter-related thrombosis (CRT) and catheter-related bloodstream infection (CRBSI). Thrombosis can obstruct the lumen and reduce dialysis efficiency, while infection directly endangers the patient's life. Therefore, functional modification of the catheter surface has become a key research direction. However, existing modified coatings have limited functions: one is to prepare anticoagulant coatings by covalently or ionically binding heparin; the other is to achieve bactericidal effects by releasing metal ions (silver, copper) or antibiotic molecules. It is difficult to achieve simultaneous anticoagulation and antibacterial effects. Moreover, the passive release mode of existing antibacterial coatings cannot respond to changes in the infection microenvironment. This passive release mode, which cannot respond to changes in the infection microenvironment, leads to the continuous release of large amounts of antibacterial agents during non-infectious periods, which can accelerate drug resistance and even cause cytotoxicity. Conversely, reducing the release dose of antibacterial agents fails to provide intensive treatment during infection outbreaks.

[0003] Therefore, the present invention proposes an anticoagulant and anti-infection coating for dialysis catheters and its preparation method, which has important practical significance. Summary of the Invention

[0004] In view of this, the present invention proposes an anticoagulant and anti-infection coating for dialysis catheters and its preparation method, aiming to solve the problems of existing modified coatings having single function and insufficient antibacterial ability.

[0005] This invention proposes a method for preparing an anticoagulant and anti-infection coating for dialysis catheters, comprising the following preparation steps: The preparation steps include the following: After pretreatment, dialysis catheters with an aminated basement layer are obtained. After undergoing dopamine / PEG co-deposition treatment, the dialysis catheter with an aminated base layer was immersed in an anhydrous dimethyl sulfoxide solution of N,N'-disuccinimidyl carbonate for active ester activation treatment, resulting in a bridge layer with N-hydroxysuccinimidyl ester active groups on its surface. By grafting a zwitterionic polymer layer onto a dialysis catheter with a bridging layer and coupling it with a heparin molecular layer, an anticoagulation and antifouling functional layer is obtained. A dialysis catheter with an anticoagulation and antifouling functional layer is coated and cross-linked with a dual-network coating solution to obtain an antibacterial gel outer layer. After the coating is applied, post-treatment is performed to obtain the anticoagulation and anti-infection dialysis catheter coating.

[0006] Furthermore, the preprocessing specifically includes: The dialysis catheter was immersed in anhydrous ethanol and ultrasonically cleaned at a frequency of 40 kHz and a power of 150 W for 20 min. After cleaning, it was dried with nitrogen. The cleaned dialysis catheter was then irradiated in an ultraviolet ozone cleaner for 15 min. After irradiation, the dialysis catheter was immersed in a 3-aminopropyltriethoxysilane-ethanol solution and reacted at a constant temperature of 50 °C for 2 h. After the reaction, it was successively immersed in ethanol and water and shaken for 5 min each time. Then it was taken out and dried with nitrogen. The concentration of 3-aminopropyltriethoxysilane in the 3-aminopropyltriethoxysilane-ethanol solution is 2-4% (v / v).

[0007] Furthermore, the dopamine / PEG co-deposition treatment specifically involves: 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol were dissolved in 10 mM Tris-HCl buffer solution at pH 8.5 to obtain a co-precipitation solution. The dialysis catheter with an aminated base layer was immersed in a co-deposition solution and reacted at 60 rpm for 2 hours in a dark environment at room temperature. After the reaction was completed, the catheter was removed, washed with water, and then vacuum dried at 45°C for 18 hours.

[0008] Furthermore, the activation treatment of the active ester specifically includes: The dopamine / PEG co-deposition treated dialysis catheter was immersed in N,N'-disuccinimide carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction was completed, it was rinsed with anhydrous dimethyl sulfoxide and ethanol. The concentration of N,N'-disuccinimidyl carbonate in the N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution is 50 mM.

[0009] Furthermore, the zwitterionic polymer layer grafting specifically involves: Weigh out terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) and PBS buffer at a ratio of (0.8-1.2) mg: 1 ml. Add the weighed terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) to 80% of the volume of PBS buffer and stir at 400 rpm in the dark for 12 h. After the stir-fry is complete, adjust the volume with the remaining PBS buffer. Filter the solution through a 0.22 μm sterile membrane to obtain the grafting solution. The dialysis catheter with the bridging layer was immersed in the grafting solution and reacted at 4°C for 12 hours.

[0010] Furthermore, the heparin molecular layer coupling specifically includes: Weigh out ethylenediamine-modified heparin sodium and PBS buffer according to the ratio of (3-7) mg: 1 ml. Add the weighed ethylenediamine-modified heparin sodium to 80% volume of PBS buffer and stir at 400 rpm for 1 h at 4 °C. After the stirring is complete, add the remaining PBS buffer to make up the volume. After the stirring is complete, filter through a 0.22 μm sterile membrane to obtain ethylenediamine-modified heparin sodium PBS solution. 1-Ethyl-(3-dimethylaminopropyl)carbodiamide was added to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 0.5-1.5 mM, and the solution was activated by shaking for 5 min to obtain the coupling solution. The dialysis catheter grafted with zwitterionic polymer layer was immersed in the coupling solution and reacted at room temperature for 6 hours. After the reaction was completed, it was washed with NaCl-PBS solution and water for 10 minutes in sequence, and then removed and vacuum dried at 30°C for 5 hours.

[0011] Furthermore, the preparation method of the dual-network coating liquid is as follows: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt were added to 0.5% (v / v) glacial acetic acid solution and stirred to dissolve, thus obtaining solution A; According to the ratio of poloxamer F127 to PBS solution of 1g:4ml, poloxamer F127 was added to PBS solution at 4℃ and stirred until clear to obtain solution B; After mixing solutions A and B in equal volumes at 4°C, the mixture and polymyxin B were added to a citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml, and stirred to disperse, according to the ratio of mixture: citric acid-modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg.

[0012] Furthermore, the coating crosslinking specifically includes: The dialysis catheter with the anticoagulation and antifouling functional layer was vertically immersed in the double network coating solution at 4°C and pulled up at a speed of 1 cm / min. After the procedure, it was transferred to an environment with 37°C and 75% humidity and left to stand for 1 hour.

[0013] Furthermore, the post-processing specifically includes: The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. The temperature was then increased to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy gamma irradiation.

[0014] The present invention also provides an anticoagulation and anti-infection dialysis catheter coating, comprising: the aminated base layer, the bridging layer, the anticoagulation and antifouling functional layer, and the antibacterial gel outer layer.

[0015] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. This invention constructs a composite layer (anticoagulation and antifouling layer) of covalently grafted poly(2-methacryloyloxyethylphosphorylcholine) and sodium heparin on the surface of a dialysis catheter, and then constructs an outer layer of pH-responsive interpenetrating network hydrogel loaded with silver nanoparticles and antimicrobial peptides on its exterior. The former physically repels proteins / platelets through the strong hydration layer of zwitterions and combines with the chemical anticoagulant activity of heparin to reduce the substrate for thrombus and biofilm formation at the source; the latter acts as a drug reservoir to release silver nanoparticles and antimicrobial peptides to ensure antimicrobial efficacy, thus achieving an integration of antifouling, anticoagulation, and antimicrobial properties.

[0016] 2. The outer layer of the antibacterial gel of this invention forms a chemical network with aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt through Schiff base bonds, which interpenetrates with the physical thermosensitive mesh of poloxamer F127, jointly encapsulating antibacterial components. When bacterial infection causes a decrease in the local microenvironment pH, the acidic Schiff base bonds undergo reversible breakage, leading to loosening of the hydrogel network and changes in swelling, thereby accelerating the release of internal antibacterial peptides and silver ions, thus achieving on-demand release of antibacterial drugs. Under normal physiological conditions (pH=7.4), the coating provides continuous, sustained-release basic antibacterial protection, reducing unnecessary drug release and the risk of drug resistance; once infection occurs, the drug release rate increases significantly within hours due to microenvironment acidification (pH 6.0).

[0017] 3. Starting with the amylation of the catheter substrate, this invention sequentially uses a series of covalent bond reactions such as silanization, polydopamine / polyethylene glycol co-deposition, active ester activation, and amidation / ring-opening reaction to firmly anchor each layer of material together from bottom to top, forming a bonding interface mainly based on chemical bonds. The bonding force between each functional layer and between the coating and the substrate is significantly enhanced. Detailed Implementation

[0018] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention. It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the present invention.

[0019] Furthermore, regarding the numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included within this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0020] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0021] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0022] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0023] This invention provides a method for preparing an anticoagulant and anti-infection coating for dialysis catheters, comprising the following preparation steps: After pretreatment, dialysis catheters with an aminated basement layer are obtained. After undergoing dopamine / PEG co-deposition treatment, the dialysis catheter with an aminated base layer was immersed in an anhydrous dimethyl sulfoxide solution of N,N'-disuccinimidyl carbonate for active ester activation treatment, resulting in a bridge layer with N-hydroxysuccinimidyl ester active groups on its surface. By grafting a zwitterionic polymer layer onto a dialysis catheter with a bridging layer and coupling it with a heparin molecular layer, an anticoagulation and antifouling functional layer is obtained. A dialysis catheter with an anticoagulation and antifouling functional layer is coated and cross-linked with a dual-network coating solution to obtain an antibacterial gel outer layer. After the coating is applied, post-treatment is performed to obtain the anticoagulation and anti-infection dialysis catheter coating.

[0024] Specifically, the dialysis catheter is preferably a polyurethane dialysis catheter.

[0025] Understandably, this invention constructs a composite layer (anticoagulation and antifouling layer) of covalently grafted poly(2-methacryloyloxyethylphosphocholine) and sodium heparin on the surface of the dialysis catheter, and then constructs an outer layer of pH-responsive interpenetrating network hydrogel loaded with silver nanoparticles and antimicrobial peptides on its exterior. The former physically repels proteins / platelets through the strong hydration layer of zwitterions and combines with the chemical anticoagulant activity of heparin to reduce the substrate for thrombus and biofilm formation at the source; the latter acts as a drug reservoir to release silver nanoparticles and antimicrobial peptides to ensure antimicrobial efficacy, thus achieving an integration of antifouling, anticoagulation, and antimicrobial properties.

[0026] It is understood that the outer layer of the antibacterial gel of this invention forms a chemical network with aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt through Schiff base bonds, and interpenetrates with the physical thermosensitive mesh of poloxamer F127, jointly encapsulating antibacterial components. When bacterial infection causes a decrease in the local microenvironment pH, the acidic Schiff base bonds undergo reversible breakage, leading to loosening of the hydrogel network and changes in swelling, thereby accelerating the release of internal antibacterial peptides and silver ions, thus achieving on-demand release of antibacterial drugs. Under normal physiological conditions (pH=7.4), the coating provides continuous, sustained-release basic antibacterial protection, reducing unnecessary drug release and the risk of drug resistance; once infection occurs, the drug release rate increases significantly within hours due to microenvironment acidification (pH 6.0).

[0027] It is understood that this invention starts with the amination of the catheter substrate and then proceeds through a series of covalent reactions, such as silanization, polydopamine / polyethylene glycol co-deposition, active ester activation, and amidation / ring-opening reaction, to firmly anchor the various layers together from bottom to top, forming a bonding interface dominated by chemical bonds. This significantly enhances the bonding force between the functional layers and between the coating and the substrate.

[0028] In this invention, the preprocessing specifically includes: The dialysis catheter was immersed in anhydrous ethanol and ultrasonically cleaned at a frequency of 40 kHz and a power of 150 W for 20 min. After cleaning, it was dried with nitrogen. The cleaned dialysis catheter was then irradiated in an ultraviolet ozone cleaner for 15 min. After irradiation, the dialysis catheter was immersed in a 3-aminopropyltriethoxysilane-ethanol solution and reacted at a constant temperature of 50 °C for 2 h. After the reaction, it was successively immersed in ethanol and water and shaken for 5 min each time. Then it was taken out and dried with nitrogen. The concentration of 3-aminopropyltriethoxysilane in the 3-aminopropyltriethoxysilane-ethanol solution is 2-4% (v / v).

[0029] Understandably, pretreatment creates a stable, uniform, and highly reactive chemical interface for the construction of all subsequent functional coatings. First, ultrasonic cleaning thoroughly removes physical contaminants from the conduit surface, ensuring a clean substrate for subsequent reactions. Then, ultraviolet ozone oxidation breaks chemical bonds in the substrate material's molecular chains and introduces active oxygen-containing groups such as hydroxyl and carboxyl groups, significantly increasing surface energy. Finally, silanization modification allows the alkoxy group at one end of the silane coupling agent (APTES) to undergo hydrolytic condensation with these oxygen-containing groups to form a strong Si-O-Si covalent bond, while the amino group at the other end aligns outwards, thus constructing a dense molecular layer rich in primary amino groups (-NH2) on the conduit surface. This aminated surface layer can form efficient and stable covalent bonds with polydopamine, reactive esters, and functional polymers in subsequent steps.

[0030] In this invention, the dopamine / PEG co-deposition treatment specifically includes: 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol were dissolved in 10 mM Tris-HCl buffer solution at pH 8.5 to obtain a co-precipitation solution. The dialysis catheter with an aminated base layer was immersed in a co-deposition solution and reacted at 60 rpm for 2 hours in a dark environment at room temperature. After the reaction was completed, the catheter was removed, washed with water, and then vacuum dried at 45°C for 18 hours.

[0031] Specifically, the Mw of the terminal amino polyethylene glycol is 2000.

[0032] Understandably, the dopamine / PEG co-deposition treatment can construct a bridge layer with both strong adhesion and high reactivity on the aminated substrate. In a weakly alkaline environment, dopamine hydrochloride undergoes oxidative self-polymerization to form a polydopamine film with extremely strong adhesion, which can be firmly anchored to the substrate surface. Simultaneously, the coexisting terminal amino polyethylene glycol participates in the reaction through its amino groups and is embedded in the network. This co-deposition process not only effectively inhibits the excessive aggregation of polydopamine by utilizing the steric hindrance effect of PEG, thereby forming a more uniform and smooth composite interface layer, but more importantly, this composite layer is rich in highly active functional groups such as phenolic hydroxyl groups and amino groups, providing abundant and stable reaction sites for subsequent efficient activation and covalent grafting of various functional molecules (such as zwitterionic polymers and heparin) through chemical crosslinking agents (such as DSC).

[0033] In this invention, the active ester activation treatment specifically includes: The dopamine / PEG co-deposition treated dialysis catheter was immersed in N,N'-disuccinimide carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction was completed, it was rinsed with anhydrous dimethyl sulfoxide and ethanol. The concentration of N,N'-disuccinimidyl carbonate in the N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution is 50 mM.

[0034] Understandably, the active ester activation treatment is used to convert the amino groups (-NH2) in the dopamine / PEG co-deposited layer into N-hydroxysuccinimide ester (NHS ester) active groups, which have higher reactivity and better selectivity. Specifically, one end of the crosslinking agent N,N'-disuccinimide carbonate (DSC) reacts with the amino group on the bridge layer, while the other end generates a stable NHS ester. Compared to the traditional EDC / NHS in-situ activation system (which may be accompanied by side reactions and uneven efficiency), this pre-activation strategy ensures that functional molecules (such as polymers with terminal amino groups) can be grafted in a controlled and efficient manner in subsequent steps by forming stable amide bonds, thereby avoiding disorderly competition between molecules.

[0035] In this invention, the zwitterionic polymer layer grafting specifically involves: The zwitterionic polymer layer grafting specifically involves: Weigh out terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) and PBS buffer at a ratio of (0.8-1.2) mg: 1 ml. Add the weighed terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) to 80% of the volume of PBS buffer and stir at 400 rpm in the dark for 12 h. After the stir-fry is complete, adjust the volume with the remaining PBS buffer. Filter the solution through a 0.22 μm sterile membrane to obtain the grafting solution. The dialysis catheter with the bridging layer was immersed in the grafting solution and reacted at 4°C for 12 hours.

[0036] Specifically, the PBS buffer concentration was 10 mM and the pH was 7.4.

[0037] Specifically, the dialysis catheter with the bridging layer is immersed in the grafting solution and reacted at 4°C for 12 hours. After the reaction is completed, the dialysis catheter is removed and cleaned with PBS buffer.

[0038] Specifically, the terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) (COOH-PMPC) can be custom-made by a chemical supply company that can provide customization services, and the degree of polymerization of the terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) (COOH-PMPC) is preferably 100.

[0039] Understandably, this step is used to covalently construct a robust, dense, and highly biocompatible antifouling molecular substrate on the activated duct substrate. Specifically, under low temperature (4°C) and long duration (12 hours) conditions, the carboxyl groups at the ends of the terminal poly(2-methacryloyloxyethyl phosphorylcholine) (COOH-PMPC) undergo an efficient amidation reaction with the N-hydroxysuccinimide ester (NHS ester) formed in the previous step on the substrate surface, thereby firmly grafting each PMPC polymer chain in a single-point anchoring manner. After grafting, the high density of phosphorylcholine groups on the polymer backbone can form a highly hydrated brush-like interface. This interface, through strong steric repulsion and chemical inertness, greatly inhibits the non-specific adsorption and adhesion of biomolecules such as plasma proteins and platelets from the source, providing an ideal chemical reaction platform for the subsequent directional and orderly grafting of heparin molecules.

[0040] In this invention, the heparin molecular layer coupling specifically refers to: Weigh out ethylenediamine-modified heparin sodium and PBS buffer according to the ratio of (3-7) mg: 1 ml. Add the weighed ethylenediamine-modified heparin sodium to 80% volume of PBS buffer and stir at 400 rpm for 1 h at 4 °C. After the stirring is complete, add the remaining PBS buffer to make up the volume. After the stirring is complete, filter through a 0.22 μm sterile membrane to obtain ethylenediamine-modified heparin sodium PBS solution. 1-Ethyl-(3-dimethylaminopropyl)carbodiamide was added to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 0.5-1.5 mM, and the solution was activated by shaking for 5 min to obtain the coupling solution. The dialysis catheter grafted with zwitterionic polymer layer was immersed in the coupling solution and reacted at room temperature for 6 hours. After the reaction was completed, it was washed with NaCl-PBS solution and water for 10 minutes in sequence, and then removed and vacuum dried at 30°C for 5 hours.

[0041] Specifically, the PBS buffer concentration was 10 mM and the pH was 7.4.

[0042] Specifically, the heparin sodium modified with ethylenediamine is preferably a low molecular weight heparin sodium with an average molecular weight of 3500-5000 Da.

[0043] Specifically, the ethylenediamine-modified heparin sodium is prepared by an EDC / NHS coupling method. The carboxyl group of heparin is activated by 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS), followed by reaction with ethylenediamine. A preferred preparation method is as follows: S1. Weigh 1.0 g of low molecular weight heparin sodium, dissolve it in 100 ml of 0.1 M MES buffer (pH 6.0), and stir at room temperature until completely dissolved to obtain a heparin sodium solution. S2. While stirring, add 1.15 g of N-hydroxysuccinimide (NHS) to the heparin sodium solution to make the final concentration 0.1 M. After the NHS is completely dissolved, add 2.88 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to make the final concentration 0.15 M. Then stir continuously for 30 min at room temperature in the dark to obtain the activated heparin sodium solution. S3. Take 6.7 mL of ethylenediamine stock solution and slowly add it dropwise to the activated heparin sodium solution while stirring. After the addition is complete, seal the reaction container with sealing film and stir continuously at room temperature in the dark for 8 hours to allow the activated carboxyl group to fully undergo amidation coupling with the amino group of ethylenediamine. S4. After the reaction is complete, add 10 mL of 1 M hydroxyamine hydrochloride solution and stir for 15 minutes to quench any remaining activated esters. Transfer all the reaction solution to a dialysis bag with a molecular weight cutoff of 3500 Da. S5. Place the dialysis bag in a 4°C environment. First, dialyze in 2L of 1M sodium chloride solution for 12 hours, changing the dialysate twice during this period to remove ionic byproducts and a small amount of unreacted small molecules. Then, transfer the dialysis bag to 2L of ultrapure water and continue dialysis for 48 hours, changing the ultrapure water every 8 hours during this period, until no chloride ions are precipitated in the dialysate when tested with silver nitrate solution. S6. Collect the clear solution in the dialysis bag, filter the solution to remove bacteria using a 0.22μm aqueous microporous membrane, and freeze-dry to obtain a solid product of heparin sodium modified with ethylenediamine.

[0044] Understandably, heparin molecular layer coupling allows for the precise and secure fixation of heparin molecules with direct anticoagulant activity onto the coating surface via a carbodiimide-mediated covalent coupling reaction on the pre-constructed PMPC antifouling molecular substrate. Specifically, the carboxyl groups of ethylenediamine-modified sodium heparin, after brief activation by EDC, can efficiently form amide bonds with amino groups pre-reserved in the PMPC polymer chain or on the substrate. This process achieves the orientation and covalent grafting of heparin molecules, ensuring the full exposure of their active functional domains. Thus, a stable chemical anticoagulant layer with active catalytic antithrombin III activity is constructed in situ on top of the passive antiprotein adhesion physical barrier provided by the PMPC layer. The two work synergistically to form a stable interface with tightly integrated antifouling and anticoagulant functions, fundamentally endowing the dialysis catheter with long-term and reliable thrombotic defense capabilities.

[0045] In this invention, the preparation method of the dual-network coating liquid is as follows: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt were added to 0.5% (v / v) glacial acetic acid solution and stirred to dissolve, thus obtaining solution A; According to the ratio of poloxamer F127 to PBS solution of 1g:4ml, poloxamer F127 was added to PBS solution at 4℃ and stirred until clear to obtain solution B; After mixing solutions A and B in equal volumes at 4°C, the mixture and polymyxin B were added to a citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml, and stirred to disperse, according to the ratio of mixture: citric acid-modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg.

[0046] Specifically, the PBS buffer concentration was 10 mM and the pH was 7.4.

[0047] The coating crosslinking specifically refers to: The dialysis catheter with the anticoagulation and antifouling functional layer was vertically immersed in the double network coating liquid at 4°C and pulled up at a speed of 1 cm / min. After forming a liquid film, it was transferred to an environment of 37°C and 75% humidity and left to stand for 1 hour.

[0048] Understandably, the coating crosslinking constructs a solid antibacterial gel outer layer, encapsulating the antibacterial component-loaded dual-network coating liquid, on the catheter surface. Vertical dip-lifting ensures uniform coating coverage. Subsequently, at 37°C, poloxamer F127 undergoes a reversible thermo-sensitive phase transition, forming a physical crosslinking network that provides immediate shape and mechanical support for the coating. Simultaneously, aldehyde-modified hyaluronic acid and the amino groups on the chitosan quaternary ammonium salt undergo an irreversible Schiff base reaction, forming a chemical crosslinking network. This physical-chemical interpenetrating dual-network structure endows the gel with excellent mechanical stability and long-term stability, and enables long-term encapsulation of silver nanoparticles and antibacterial peptides. The unique pH sensitivity of the Schiff base bond is crucial; it allows the outer layer to maintain stable and sustained release in normal physiological environments. Once it senses local microenvironment acidification (pH decrease) caused by bacterial infection, the bond breaks, the network swells, and the antibacterial component is intelligently and rapidly released, achieving a precise response from prevention to infection-triggered intensive treatment.

[0049] In this invention, the post-processing specifically includes: The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. The temperature was then increased to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy gamma irradiation.

[0050] Understandably, the post-processing involves repeated rinsing with sterile PBS to remove any unreacted reagents or byproducts, such as glutaraldehyde, that may remain after cross-linking and curing, ensuring biocompatibility. Subsequent freeze-drying gently removes moisture from the coating at low temperatures, creating a stable porous network structure and preventing functional molecule inactivation or coating cracking that may occur with high-temperature drying. Finally, sterilization is achieved using 25 kGy gamma irradiation. High-energy photons can penetrate the material and effectively kill all microorganisms without damaging the covalent bond structure. This dose has been extensively validated to be sufficient to achieve the sterility assurance level for medical devices, thus providing the product with reliable sterility and long-term storage stability without introducing chemical residues.

[0051] The present invention also provides an anticoagulation and anti-infection dialysis catheter coating, comprising: the aminated base layer, the bridging layer, the anticoagulation and antifouling functional layer, and the antibacterial gel outer layer.

[0052] Example 1 Reagent preparation Co-deposition solution: Dissolve 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol (Mw=2000) in 10 mM Tris-HCl buffer solution at pH 8.5; Grafting solution: Terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine):PBS buffer was weighed at a ratio of 0.8 mg:1 ml. 10 mM, pH 7.4 PBS buffer was added to 80% of the PBS buffer, and the mixture was stirred at 400 rpm in the dark for 12 h. After the stirring was complete, the volume was adjusted using the remaining PBS buffer. The mixture was then filtered through a 0.22 μm sterile membrane. The degree of polymerization of the terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) was 100, and it was custom-synthesized by Xi'an Ruixi Biotechnology Co., Ltd. Ethylenediamine-modified heparin sodium PBS solution: Weigh ethylenediamine-modified heparin sodium and 10mM, pH=7.4 PBS buffer at a ratio of 3mg:1ml. Add the weighed ethylenediamine-modified heparin sodium to 80% of the volume of PBS buffer and stir at 400rpm for 1h at 4℃. After stirring, add the remaining PBS buffer to make up the volume. Filter the solution through a 0.22μm sterile membrane to obtain the ethylenediamine-modified heparin sodium PBS solution. The ethylenediamine-modified heparin sodium is prepared by the above method. Double-network coating solution A: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, add aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt to 0.5% (v / v) glacial acetic acid solution and stir to dissolve; Double network coating solution B: Poloxamer F127 was added to PBS solution at 4°C, 10mM, pH=7.4 at a ratio of 1g:4ml, and stirred until clear.

[0053] Preparation method: S1. Immerse the polyurethane dialysis catheter in anhydrous ethanol and ultrasonically clean it at a frequency of 40kHz and a power of 150W for 20 minutes. Then dry it with nitrogen. Place the cleaned dialysis catheter in an ultraviolet ozone cleaner for 15 minutes. Then immerse the irradiated dialysis catheter in a 2% (v / v) concentration of 3-aminopropyltriethoxysilane-ethanol solution and react it at 50℃ for 2 hours. After the reaction, immerse it in ethanol and water in sequence and shake it for 5 minutes each time. Then take it out and dry it with nitrogen to obtain a dialysis catheter with an aminated base layer. S2. The dialysis catheter with the aminated substrate layer was immersed in the co-deposition solution and reacted at 60 rpm for 2 h in a dark environment at room temperature. After the reaction, it was taken out, washed with water, and vacuum dried at 45 °C for 18 h. The dried dialysis catheter was then immersed in a 50 mM N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction, it was rinsed with anhydrous dimethyl sulfoxide and ethanol to obtain a bridge layer with N-hydroxysuccinimidyl ester active groups on the surface. S3. Immerse the dialysis catheter with the bridging layer in the grafting solution and react at 4°C for 12 hours. After the reaction is complete, remove the dialysis catheter and clean it with PBS buffer. S4. Add 1-ethyl-(3-dimethylaminopropyl)carbodiene to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 0.5 mM, shake and activate for 5 min to obtain a coupling solution. Immerse the cleaned dialysis catheter in the coupling solution and react at room temperature for 6 h. After the reaction, wash with NaCl-PBS solution and water for 10 min in sequence, then remove and vacuum dry at 30 °C for 5 h to obtain an anticoagulation and antifouling functional layer. S5. Mix the double-network coating solution A and double-network coating solution B in equal volumes at 4°C. Then, add the mixture and polymyxin B to the citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml according to the ratio of mixture: citric acid modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg. Stir and disperse to obtain a double-network coating solution. Vertically immerse the dialysis catheter with anticoagulation and antifouling functional layer into the double-network coating solution at 4°C and pull it up at a speed of 1 cm / min. After forming a liquid film, transfer it to an environment of 37°C and 75% humidity and let it stand for 1 hour to obtain the antibacterial gel outer layer. S6. The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. Then, the temperature was raised to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy γ-ray irradiation to obtain the anticoagulant and anti-infection dialysis catheter coating.

[0054] Example 2 Reagent preparation Co-deposition solution: Dissolve 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol (Mw=2000) in 10 mM Tris-HCl buffer solution at pH 8.5; Grafting solution: Terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine):PBS buffer was weighed at a ratio of 1 mg:1 ml. 10 mM, pH 7.4 PBS buffer was added to 80% of the PBS buffer, and the mixture was stirred at 400 rpm in the dark for 12 h. After the stirring was complete, the volume was adjusted using the remaining PBS buffer. The mixture was then filtered through a 0.22 μm sterile membrane. The degree of polymerization of the terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) was 100, and it was custom-synthesized by Xi'an Ruixi Biotechnology Co., Ltd. Ethylenediamine-modified heparin sodium PBS solution: Weigh ethylenediamine-modified heparin sodium and 10mM, pH=7.4 PBS buffer at a ratio of 5mg:1ml. Add the weighed ethylenediamine-modified heparin sodium to 80% of the volume of PBS buffer and stir at 400rpm for 1h at 4℃. After stirring, add the remaining PBS buffer to make up the volume. Filter the solution through a 0.22μm sterile membrane to obtain the ethylenediamine-modified heparin sodium PBS solution. The ethylenediamine-modified heparin sodium is prepared by the above method. Double-network coating solution A: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, add aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt to 0.5% (v / v) glacial acetic acid solution and stir to dissolve; Double network coating solution B: Poloxamer F127 was added to PBS solution at 4°C, 10mM, pH=7.4 at a ratio of 1g:4ml, and stirred until clear.

[0055] Preparation method: S1. Immerse the polyurethane dialysis catheter in anhydrous ethanol and ultrasonically clean it at a frequency of 40kHz and a power of 150W for 20 minutes. Then dry it with nitrogen. Place the cleaned dialysis catheter in an ultraviolet ozone cleaner for 15 minutes. Then immerse the irradiated dialysis catheter in a 3% (v / v) concentration of 3-aminopropyltriethoxysilane-ethanol solution and react it at 50℃ for 2 hours. After the reaction, immerse it in ethanol and water in sequence and shake it for 5 minutes each time. Then take it out and dry it with nitrogen to obtain a dialysis catheter with an aminated base layer. S2. The dialysis catheter with the aminated substrate layer was immersed in the co-deposition solution and reacted at 60 rpm for 2 h in a dark environment at room temperature. After the reaction, it was taken out, washed with water, and vacuum dried at 45 °C for 18 h. The dried dialysis catheter was then immersed in a 50 mM N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction, it was rinsed with anhydrous dimethyl sulfoxide and ethanol to obtain a bridge layer with N-hydroxysuccinimidyl ester active groups on the surface. S3. Immerse the dialysis catheter with the bridging layer in the grafting solution and react at 4°C for 12 hours. After the reaction is complete, remove the dialysis catheter and clean it with PBS buffer. S4. Add 1-ethyl-(3-dimethylaminopropyl)carbodiene to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 1 mM, shake and activate for 5 min to obtain a coupling solution. Immerse the cleaned dialysis catheter in the coupling solution and react at room temperature for 6 h. After the reaction is complete, wash with NaCl-PBS solution and water for 10 min in sequence, then remove and vacuum dry at 30 °C for 5 h to obtain an anticoagulation and antifouling functional layer. S5. Mix the double-network coating solution A and double-network coating solution B in equal volumes at 4°C. Then, add the mixture and polymyxin B to the citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml according to the ratio of mixture: citric acid modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg. Stir and disperse to obtain a double-network coating solution. Vertically immerse the dialysis catheter with anticoagulation and antifouling functional layer into the double-network coating solution at 4°C and pull it up at a speed of 1 cm / min. After forming a liquid film, transfer it to an environment of 37°C and 75% humidity and let it stand for 1 hour to obtain the antibacterial gel outer layer. S6. The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. Then, the temperature was raised to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy γ-ray irradiation to obtain the anticoagulant and anti-infection dialysis catheter coating.

[0056] Example 3 Reagent preparation Co-deposition solution: Dissolve 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol (Mw=2000) in 10 mM Tris-HCl buffer solution at pH 8.5; Grafting solution: Terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine):PBS buffer was weighed at a ratio of 1.2 mg:1 ml. 10 mM, pH 7.4 PBS buffer was added to 80% of the PBS buffer, and the mixture was stirred at 400 rpm in the dark for 12 h. After the stirring was complete, the volume was adjusted using the remaining PBS buffer. The mixture was then filtered through a 0.22 μm sterile membrane. The degree of polymerization of the terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) was 100, and it was custom-synthesized by Xi'an Ruixi Biotechnology Co., Ltd. Ethylenediamine-modified heparin sodium PBS solution: Weigh ethylenediamine-modified heparin sodium and 10mM, pH=7.4 PBS buffer at a ratio of 7mg:1ml. Add the weighed ethylenediamine-modified heparin sodium to 80% of the volume of PBS buffer and stir at 400rpm for 1h at 4℃. After stirring, add the remaining PBS buffer to make up the volume. Filter the solution through a 0.22μm sterile membrane to obtain the ethylenediamine-modified heparin sodium PBS solution. The ethylenediamine-modified heparin sodium is prepared by the above method. Double-network coating solution A: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, add aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt to 0.5% (v / v) glacial acetic acid solution and stir to dissolve; Double network coating solution B: Poloxamer F127 was added to PBS solution at 4°C, 10mM, pH=7.4 at a ratio of 1g:4ml, and stirred until clear.

[0057] Preparation method: S1. Immerse the polyurethane dialysis catheter in anhydrous ethanol and ultrasonically clean it at a frequency of 40kHz and a power of 150W for 20 minutes. Then dry it with nitrogen. Place the cleaned dialysis catheter in an ultraviolet ozone cleaner for 15 minutes. Then immerse the irradiated dialysis catheter in a 4% (v / v) concentration of 3-aminopropyltriethoxysilane-ethanol solution and react it at 50℃ for 2 hours. After the reaction, immerse it in ethanol and water in sequence and shake it for 5 minutes each time. Then take it out and dry it with nitrogen to obtain a dialysis catheter with an aminated base layer. S2. The dialysis catheter with the aminated substrate layer was immersed in the co-deposition solution and reacted at 60 rpm for 2 h in a dark environment at room temperature. After the reaction, it was taken out, washed with water, and vacuum dried at 45 °C for 18 h. The dried dialysis catheter was then immersed in a 50 mM N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction, it was rinsed with anhydrous dimethyl sulfoxide and ethanol to obtain a bridge layer with N-hydroxysuccinimidyl ester active groups on the surface. S3. Immerse the dialysis catheter with the bridging layer in the grafting solution and react at 4°C for 12 hours. After the reaction is complete, remove the dialysis catheter and clean it with PBS buffer. S4. 1-Ethyl-(3-dimethylaminopropyl)carbodiene was added to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 1.5 mM. The solution was shaken and activated for 5 min to obtain a coupling solution. The cleaned dialysis catheter was immersed in the coupling solution and reacted at room temperature for 6 h. After the reaction was completed, the catheter was washed with NaCl-PBS solution and water for 10 min in sequence and then removed and vacuum dried at 30 °C for 5 h to obtain an anticoagulation and antifouling functional layer. S5. Mix the double-network coating solution A and double-network coating solution B in equal volumes at 4°C. Then, add the mixture and polymyxin B to the citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml according to the ratio of mixture: citric acid modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg. Stir and disperse to obtain a double-network coating solution. Vertically immerse the dialysis catheter with anticoagulation and antifouling functional layer into the double-network coating solution at 4°C and pull it up at a speed of 1 cm / min. After forming a liquid film, transfer it to an environment of 37°C and 75% humidity and let it stand for 1 hour to obtain the antibacterial gel outer layer. S6. The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. Then, the temperature was raised to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy γ-ray irradiation to obtain the anticoagulant and anti-infection dialysis catheter coating.

[0058] Test Example 1 (Antibacterial and Anticoagulant Function Test) 1.1 Anticoagulation Function Test: Test samples: A 2cm section of the anticoagulant and anti-infection dialysis catheter prepared in Example 2 of this invention was taken as the experimental group; a 2cm section of a commercially available dialysis catheter with heparin coating (Cochlear central venous catheter for hemodialysis) was taken as control group 1; a 2cm section of the uncoated polyurethane dialysis catheter used in the example of this invention was taken as control group 2, with 3 replicates in each group.

[0059] Test steps: S1. Collect fresh venous blood from healthy volunteers and use 3.2% sodium citrate at a volume ratio of 1:9 for anticoagulation.

[0060] S2. Quickly inject 0.5 mL of hypercalcified whole blood (with 0.1 M CaCl2 solution added) into a transparent siliconized glass tube containing the catheter sample.

[0061] S3. Immediately place the glass tube in a 37°C constant temperature water bath and install it on the dynamic coagulation analyzer, continuously tilting and rotating it at a speed of 10° / second.

[0062] S4. Record the precise time from the start of the process until the blood completely clots and stops flowing, i.e., dynamic clotting time, through the instrument's optical sensor or visual observation.

[0063] S5. Repeat the test for each group of samples and take the mean ± standard deviation.

[0064] 1.2 Antibacterial function test: Test samples: Same as those for antibacterial function testing; Test steps: S1. Using standard strains of Staphylococcus aureus (ATCC 6538) and Escherichia coli (ATCC 25922), inoculate into TSB liquid medium and culture at 37°C with shaking until the logarithmic growth phase.

[0065] S2. Adjust the bacterial concentration to 1×10⁻⁶ using PBS. 6 CFU / mL.

[0066] S3. Immerse each catheter sample in 1 mL of bacterial suspension and place it in a 24-well plate.

[0067] S4. Incubate in a constant temperature shaker at 37°C for 2 hours (to test rapid sterilization) and 24 hours (to test long-term antibacterial effect and biofilm inhibition).

[0068] S5. After incubation, transfer each sample to a centrifuge tube containing 5 mL of sterile PBS, vortex for 1 minute, and sonicate (40 kHz, 60 W, 2 minutes) to wash away and disperse surface bacteria.

[0069] S6. Take 100 μL of elution buffer or its appropriate dilution, spread it on a TSA plate, incubate at 37°C for 24 hours, and count the colonies.

[0070] S7. Calculate the sterilization rate: Sterilization rate (%) = [(number of colonies in the control group - number of colonies in the experimental group) / number of colonies in the control group] × 100%.

[0071] 1.3 Test results (as shown in Table 1) Table 1 Results of anticoagulation and antibacterial function tests

[0072] It is evident that the coating prepared by this invention outperforms existing technologies in core performance. Its anticoagulation duration (152.3 minutes) is 1.8 times that of commercially available heparin-coated catheters (84.6 minutes). At the same time, it can achieve nearly 100% rapid contact sterilization within 2 hours (commercially available products have no significant antibacterial properties) and completely inhibit bacterial and biofilm formation within 24 hours. It successfully solves the clinical pain point of single-function coatings being "anticoagulating but not antibacterial" and achieves synergistic protection.

[0073] Test Example 2 (Coating Adhesion and Long-Term Stability Test) 2.1 Coating adhesion test (cross-cut adhesion test) Sample preparation: Coated substrates were prepared using polyurethane sheets as raw materials and the preparation method of Example 2 of this invention, which served as samples.

[0074] Test steps: S1. Using a multi-blade cutting tool, make 6×6 squares spaced 1mm apart on the coating surface, ensuring the cutting depth reaches the substrate.

[0075] S2. Gently sweep away the debris with a soft brush.

[0076] S3. Firmly adhere the special pressure-sensitive tape to the grid area and press it down firmly with an eraser.

[0077] S4. Tear off the tape quickly and smoothly at a 60° angle.

[0078] S5. Observe the grid area under an optical microscope and rate it according to ASTM D3359-17 standard: Grade 0 (smooth edges, no peeling) is the best; Grade 5 (peeling area >65%) is the worst.

[0079] 2.2 Stability Test Test samples: Coated slides after coating adhesion test and anticoagulant and anti-infection dialysis catheters prepared in Example 2 of this invention, wherein the dialysis catheters were set up in 5 replicates; Test method: S1. Record the initial mass of the sample (W0). Immerse the sample in PBS buffer (pH=7.4) at 37°C and constant speed shaking (60 rpm).

[0080] S2. Samples are taken out at regular intervals on days 7, 14, 21, and 28.

[0081] S3. After washing the sample with ultrapure water, place it in a vacuum drying oven (35℃) and dry it to constant weight. Record the mass (W). t ).

[0082] S4. Calculate the mass loss rate: Mass loss rate (%) = [(W0 - W...] t ) / W0]×100%.

[0083] S5. After soaking on day 28, the dialysis catheter samples were subjected to dynamic coagulation time test and sterilization rate (24-hour antibacterial test) using the same method as in Test Example 1, and the function retention rate was calculated.

[0084] 2.3 Test results (as shown in Table 2-3) Table 2. Test results of coating adhesion rate and mass loss rate

[0085] As can be seen from the data, the coating experienced minimal mass loss and no change in adhesion during the first 7 days, proving that its initial curing was complete. Subsequently, the mass loss was slow and almost linear (cumulative <3% over 28 days), and the adhesion grade remained stable at the optimal level 1 from day 14 onwards (with only minor peeling at the cut). This indicates that the coating has a dense structure, degrades slowly, and bonds extremely firmly to the substrate, meeting the physical stability requirements for long-term storage.

[0086] Table 3. Results of functional stability test of coating after 28 days of immersion

[0087] It is evident that after 28 days of simulated bodily fluid environment, the coating's core anticoagulant and antibacterial functions maintained a retention rate of over 90%.

[0088] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the specific implementation of the present invention. Any modifications or equivalent substitutions that do not depart from the spirit and scope of the present invention should be covered within the scope of protection of the claims of the present invention.

Claims

1. A method for preparing an anticoagulant and anti-infection coating for dialysis catheters, characterized in that, The preparation steps include the following: After pretreatment, dialysis catheters with an aminated basement layer are obtained. After undergoing dopamine / PEG co-deposition treatment, the dialysis catheter with an aminated base layer was immersed in an anhydrous dimethyl sulfoxide solution of N,N'-disuccinimidyl carbonate for active ester activation treatment, resulting in a bridge layer with N-hydroxysuccinimidyl ester active groups on its surface. By grafting a zwitterionic polymer layer onto a dialysis catheter with a bridging layer and coupling it with a heparin molecular layer, an anticoagulation and antifouling functional layer is obtained. A dialysis catheter with an anticoagulation and antifouling functional layer is coated and cross-linked with a dual-network coating solution to obtain an antibacterial gel outer layer. After the coating is applied, post-treatment is performed to obtain the anticoagulation and anti-infection dialysis catheter coating.

2. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 1, characterized in that, The preprocessing specifically includes: The dialysis catheter was immersed in anhydrous ethanol and ultrasonically cleaned at a frequency of 40 kHz and a power of 150 W for 20 min. After cleaning, it was dried with nitrogen. The cleaned dialysis catheter was then irradiated in an ultraviolet ozone cleaner for 15 min. After irradiation, the dialysis catheter was immersed in a 3-aminopropyltriethoxysilane-ethanol solution and reacted at a constant temperature of 50 °C for 2 h. After the reaction, it was successively immersed in ethanol and water and shaken for 5 min each time. Then it was taken out and dried with nitrogen. The concentration of 3-aminopropyltriethoxysilane in the 3-aminopropyltriethoxysilane-ethanol solution is 2-4% (v / v).

3. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 2, characterized in that, The dopamine / PEG co-deposition treatment specifically involves: 10 mM dopamine hydrochloride and 20 mM amino-terminated polyethylene glycol were dissolved in 10 mM Tris-HCl buffer solution at pH 8.5 to obtain a co-precipitation solution. The dialysis catheter with an aminated base layer was immersed in a co-deposition solution and reacted at 60 rpm for 2 hours in a dark environment at room temperature. After the reaction was completed, the catheter was removed, washed with water, and then vacuum dried at 45°C for 18 hours.

4. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 3, characterized in that, The activation treatment of the active ester is specifically as follows: The dopamine / PEG co-deposition treated dialysis catheter was immersed in N,N'-disuccinimide carbonate-anhydrous dimethyl sulfoxide solution and reacted at room temperature for 4 h. After the reaction was completed, it was rinsed with anhydrous dimethyl sulfoxide and ethanol. The concentration of N,N'-disuccinimidyl carbonate in the N,N'-disuccinimidyl carbonate-anhydrous dimethyl sulfoxide solution is 50 mM.

5. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 4, characterized in that, The zwitterionic polymer layer grafting specifically involves: Weigh out terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) and PBS buffer at a ratio of (0.8-1.2) mg: 1 ml. Add the weighed terminal carboxylated poly(2-methacryloyloxyethyl phosphorylcholine) to 80% of the volume of PBS buffer and stir at 400 rpm in the dark for 12 h. After the stir-fry is complete, adjust the volume with the remaining PBS buffer. Filter the solution through a 0.22 μm sterile membrane to obtain the grafting solution. The dialysis catheter with the bridging layer was immersed in the grafting solution and reacted at 4°C for 12 hours.

6. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 5, characterized in that, The heparin molecular layer coupling specifically refers to: Weigh out ethylenediamine-modified heparin sodium and PBS buffer according to the ratio of (3-7) mg: 1 ml. Add the weighed ethylenediamine-modified heparin sodium to 80% volume of PBS buffer and stir at 400 rpm for 1 h at 4 °C. After the stirring is complete, add the remaining PBS buffer to make up the volume. After the stirring is complete, filter through a 0.22 μm sterile membrane to obtain ethylenediamine-modified heparin sodium PBS solution. 1-Ethyl-(3-dimethylaminopropyl)carbodiamide was added to a heparin sodium PBS solution modified with ethylenediamine to a final concentration of 0.5-1.5 mM, and the solution was activated by shaking for 5 min to obtain the coupling solution. The dialysis catheter grafted with zwitterionic polymer layer was immersed in the coupling solution and reacted at room temperature for 6 hours. After the reaction was completed, it was washed with NaCl-PBS solution and water for 10 minutes in sequence, and then removed and vacuum dried at 30°C for 5 hours.

7. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 6, characterized in that, The preparation method of the dual-network coating liquid is as follows: According to the ratio of aldehyde-modified hyaluronic acid to chitosan quaternary ammonium salt of 10 mg: 1 ml, aldehyde-modified hyaluronic acid and chitosan quaternary ammonium salt were added to 0.5% (v / v) glacial acetic acid solution and stirred to dissolve, thus obtaining solution A; According to the ratio of poloxamer F127 to PBS solution of 1g:4ml, poloxamer F127 was added to PBS solution at 4℃ and stirred until clear to obtain solution B; After mixing solutions A and B in equal volumes at 4°C, the mixture and polymyxin B were added to a citric acid-modified silver nanoparticle suspension with a concentration of 0.5 mg / ml, and stirred to disperse, according to the ratio of mixture: citric acid-modified silver nanoparticle suspension: polymyxin B of 4 ml: 2 ml: 1 mg.

8. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 7, characterized in that, The coating crosslinking specifically refers to: The dialysis catheter with the anticoagulation and antifouling functional layer was vertically immersed in the double network coating solution at 4°C and pulled up at a speed of 1 cm / min. After the procedure, it was transferred to an environment with 37°C and 75% humidity and left to stand for 1 hour.

9. The method for preparing an anticoagulant and anti-infection coating for a dialysis catheter according to claim 8, characterized in that, The post-processing specifically includes: The dialysis catheter with the antibacterial gel outer layer was immersed and rinsed three times with 10mM PBS buffer (pH=7.4) for 10 minutes each time. After that, it was pre-frozen at -80℃ for 10 hours, then dried at -30℃ and 10Pa vacuum for 36 hours. The temperature was then increased to 25℃ at a rate of 5℃ / h and held for 5 hours. After that, the dried dialysis catheter was placed under a cobalt-60 source and sterilized by 25kGy gamma irradiation.

10. An anticoagulant and anti-infective dialysis catheter coating prepared by the method for preparing an anticoagulant and anti-infective dialysis catheter coating according to any one of claims 1-9, characterized in that, include: The aminated base layer, bridging layer, anti-coagulation and antifouling functional layer, and antibacterial gel outer layer are described.